Profile data is unavailable for this security.
About the company
Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopaedics, and Spine that help improve patient and hospital outcomes. Its products are sold in approximately 75 countries through Company-owned subsidiaries and branches, as well as, third-party dealers and distributors. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a range of medical specialties. Its business segments include MedSurg and Neurotechnology and Orthopaedics and Spine. Its subsidiaries include Alcott Indemnity Company, Arrinex, Inc., Berchtold Corporation, and BioMimetic Therapeutics, LLC.
- Revenue in USD (TTM)17.95bn
- Net income in USD2.46bn
- Incorporated1946
- Employees46.00k
- LocationStryker Corp2825 Airview BlvdKALAMAZOO 49002United StatesUSA
- Phone+1 (269) 389-2600
- Fax+1 (269) 385-1062
- Websitehttps://www.stryker.com/
Mergers & acquisitions
| Acquired company | SYK:NYQ since announced | Transaction value |
|---|---|---|
| Vocera Communications Inc | -13.43% | 2.97bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DexCom, Inc. | 2.79bn | 230.00m | 45.02bn | 6.30k | 217.72 | 24.67 | 117.95 | 16.12 | 0.5354 | 0.5354 | 6.71 | 4.72 | 0.5773 | 2.87 | 5.11 | 443,301.60 | 4.75 | 5.56 | 5.72 | 6.50 | 65.97 | 67.29 | 8.24 | 8.91 | 3.43 | 12.92 | 0.5266 | 0.00 | 27.08 | 33.69 | -68.66 | -- | 47.52 | -- |
| Edwards Lifesciences Corp | 5.36bn | 1.46bn | 45.66bn | 15.70k | 31.79 | 7.36 | 28.61 | 8.51 | 2.32 | 2.32 | 8.54 | 10.04 | 0.6386 | 1.51 | 8.80 | 341,643.30 | 17.37 | 15.99 | 19.56 | 18.95 | 78.93 | 75.11 | 27.20 | 23.63 | 3.00 | -- | 0.0875 | 0.00 | 19.29 | 12.04 | 82.55 | 21.42 | 8.69 | -- |
| Boston Scientific Corporation | 12.57bn | 597.00m | 65.06bn | 41.00k | 109.43 | 3.69 | 37.63 | 5.18 | 0.4151 | 0.4151 | 8.74 | 12.32 | 0.3938 | 2.31 | 7.10 | 306,512.20 | 2.04 | 3.26 | 2.32 | 4.00 | 68.89 | 69.40 | 5.19 | 8.03 | 0.9456 | 6.77 | 0.3273 | 0.00 | 19.92 | 7.23 | 956.52 | 23.20 | 1.75 | -- |
| Becton Dickinson and Co | 18.87bn | 1.55bn | 69.77bn | 77.00k | 45.79 | 2.76 | 18.49 | 3.70 | 5.38 | 5.88 | 65.72 | 89.22 | 0.3534 | 3.41 | 8.05 | 245,064.90 | 3.06 | 2.21 | 3.54 | 2.51 | 44.92 | 45.78 | 8.66 | 6.55 | 0.6295 | 6.58 | 0.3885 | 86.56 | -1.36 | 9.31 | 2.05 | 8.45 | 6.00 | -- |
| Stryker Corporation | 17.95bn | 2.46bn | 90.02bn | 46.00k | 37.00 | 5.47 | 26.17 | 5.02 | 6.43 | 6.43 | 46.95 | 43.51 | 0.5119 | 1.77 | 6.06 | 390,173.90 | 7.01 | 6.73 | 8.04 | 7.95 | 63.95 | 65.57 | 13.69 | 13.16 | 1.19 | -- | 0.4366 | 42.39 | 19.21 | 8.60 | 24.70 | 3.90 | 1.39 | 11.20 |
| Intuitive Surgical, Inc. | 6.12bn | 1.38bn | 95.31bn | 9.79k | 71.43 | 8.28 | 54.21 | 15.58 | 3.78 | 3.78 | 16.77 | 32.59 | 0.4671 | 2.77 | 7.92 | 624,721.80 | 10.62 | 14.12 | 11.67 | 15.68 | 67.77 | 68.83 | 22.73 | 29.38 | 4.42 | -- | 0.00 | 0.00 | 31.01 | 16.10 | 60.72 | 18.22 | 45.67 | -- |
| Medtronic PLC | 30.81bn | 4.32bn | 104.80bn | 95.00k | 24.47 | 2.02 | 14.88 | 3.40 | 3.22 | 3.22 | 23.01 | 39.00 | 0.3331 | 2.12 | 5.54 | 324,294.80 | 4.70 | 5.08 | 5.35 | 5.72 | 67.62 | 68.46 | 14.10 | 15.45 | 1.41 | 19.75 | 0.3383 | 62.61 | 5.21 | 1.30 | 43.97 | 4.58 | 1.76 | 7.94 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 28.40m | 7.51% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2022 | 20.13m | 5.32% |
| Greenleaf Asset Management, Inc.as of 30 Sep 2022 | 19.81m | 5.24% |
| Wellington Management Co. LLPas of 30 Sep 2022 | 17.65m | 4.67% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 15.62m | 4.13% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 14.05m | 3.71% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2022 | 12.63m | 3.34% |
| Fundsmith LLPas of 30 Sep 2022 | 7.26m | 1.92% |
| Geode Capital Management LLCas of 30 Sep 2022 | 5.70m | 1.51% |
| Franklin Advisers, Inc.as of 30 Sep 2022 | 4.42m | 1.17% |
